Cite
Therapies for inflammatory bowel disease do not pose additional risks for adverse outcomes of SARS-CoV 2 infection: an IG-IBD study
MLA
Bezzio, C., et al. Therapies for Inflammatory Bowel Disease Do Not Pose Additional Risks for Adverse Outcomes of SARS-CoV 2 Infection: An IG-IBD Study. Jan. 2021. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....0e9583b014c44969ace8f5c5288d3529&authtype=sso&custid=ns315887.
APA
Bezzio, C., Armuzzi, A., Furfaro, F., Ardizzone, S., Milla, M., Carparelli, S., Orlando, A., Caprioli, F. A., Castiglione, F., Vigano, C., Ribaldone, D. G., Zingone, F., Monterubbianesi, R., Imperatore, N., Festa, S., Daperno, M., Scucchi, L., Ferronato, A., Pastorelli, L., … Conforti, F. S. (2021). Therapies for inflammatory bowel disease do not pose additional risks for adverse outcomes of SARS-CoV 2 infection: an IG-IBD study.
Chicago
Bezzio, C., A. Armuzzi, F. Furfaro, S. Ardizzone, M. Milla, S. Carparelli, A. Orlando, et al. 2021. “Therapies for Inflammatory Bowel Disease Do Not Pose Additional Risks for Adverse Outcomes of SARS-CoV 2 Infection: An IG-IBD Study,” January. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....0e9583b014c44969ace8f5c5288d3529&authtype=sso&custid=ns315887.